GSK Set To Begin Trials On Japan’s Third Bird-Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
Japan's Health Ministry gave GlaxoSmithKline fast-track status for its bird-flu vaccine, clearing the way for clinical trials to begin as early as this year. If successful, the GSK pre-pandemic vaccine against the H5N1 flu virus would be the third approved for marketing in Japan, which already has stockpiled enough doses for 20 million people. GSK has approval for its vaccine in the European Union. The medical community would like to have as many choices of vaccines as possible because of uncertainties surrounding a possible pandemic of the virus. (Click here for more - a subscription may be requiredYou may also be interested in...
Health And Wellness Product Trademark Review 10 December, 2019
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Expert Panel Affirms ‘Continued Marketing’ Of Ambrisentan, Everolimus In India
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
US DoJ Has 'Key Focus' On Supplement Industry, Adds 6 Attorneys To Sector
"It is just common sense that there's going to be fraud where you have the combination of high growth, developing science, imported products or ingredients and limited oversight," says David Morrell, deputy assistant US attorney in DoJ'd Consumer Protection Branch. CPB is adhering to executive order President Trump made earlier in 2019 instructing federal agencies to enforced based on regulations, not on guidance.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports